News & Events CTI Announces Partnership with Rare Disease Day 2016

CTI Announces Partnership with Rare Disease Day 2016

February 25, 2016

CTI Clinical Trial & Consulting Services Announces Partnership with Rare Disease Day 2016

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ February 25, 2016] CTI Clinical Trial and Consulting Services (CTI) announces their partnership with Rare Disease Day for the third consecutive year, taking place February 29, 2016.

Rare Disease Day takes place on the last day of February each year, with the objective to raise awareness about rare diseases and their impact on patients' lives. Since Rare Disease Day was first launched by EURORDIS and its Council of National Alliances in 2008, thousands of events have taken place throughout the world reaching hundreds of thousands of people. 

CTI employees are participating in a global 200,000 Step Challenge to raise awareness for those with rare disease around the world (in the United States, any disease affecting fewer than 200,000 people is considered rare). Employees are tracking their steps from February 1 - February 29 in a virtual step challenge, with tens of millions of steps recorded to date. Funds raised through the CTI Step Challenge will be donated to the International Niemann-Pick Disease Alliance and the Tuberous Sclerosis Alliance, both chosen because of the relationship to recent rare disease projects the company is working on. CTI is committed to donating back to those in need, especially in communities and areas directly related to our employees, sponsors, and partners.

CTI is a leader in rare disease and orphan disease research with more than 80% of our work falling into this category across North America, South America, Europe and Pacific-Asia, resulting in several dozen drug approvals.

Rare Disease Day 2016 2

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com

Original Press Release

Subscribe to our mailing list

* indicates required